Dotatate
- Generic Name
- Dotatate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C65H90N14O19S2
- CAS Number
- 177943-88-3
- Unique Ingredient Identifier
- MRL3739G66
- Associated Conditions
- -
- Associated Therapies
- -
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Phase 2
Recruiting
- Conditions
- Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 740
- Registration Number
- NCT04074135
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Phase 2
Completed
- Conditions
- Hippel-Lindau DiseaseNeuroendocrine TumorsVon Hippel-Lindau Syndrome
- Interventions
- Drug: 68Gallium DOTATATEProcedure: Radio-guided surgery
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 341
- Registration Number
- NCT01967537
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath